PANCURONIUM BROMIDE Drug Patent Profile

When do Pancuronium Bromide patents expire, and what generic alternatives are available?

Pancuronium Bromide is a drug marketed by Dr Reddys, Elkins Sinn, Hospira, and Igi Labs Inc. and is included in eleven NDAs.

The generic ingredient in PANCURONIUM BROMIDE is pancuronium bromide. There are six drug master file entries for this compound. Additional details are available on the pancuronium bromide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Pancuronium Bromide

A generic version of PANCURONIUM BROMIDE was approved as pancuronium bromide by DR REDDYS on July 31^st, 1990.

Summary for PANCURONIUM BROMIDE

US Patents:	0
Applicants:	4
NDAs:	11
Raw Ingredient (Bulk) Api Vendors:	58
Patent Applications:	2,801
DailyMed Link:	PANCURONIUM BROMIDE at DailyMed

Medical Subject Heading (MeSH) Categories for PANCURONIUM BROMIDE

Neuromuscular Nondepolarizing Agents

Nicotinic Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for PANCURONIUM BROMIDE

M03AC	Other quaternary ammonium compounds
M03A	MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS
M03	MUSCLE RELAXANTS
M	Musculo-skeletal system

US Patents and Regulatory Information for PANCURONIUM BROMIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Dr Reddys	PANCURONIUM BROMIDE	pancuronium bromide	INJECTABLE;INJECTION	072759-001	Jul 31, 1990		RX	No	Yes
Hospira	PANCURONIUM BROMIDE	pancuronium bromide	INJECTABLE;INJECTION	072321-001	Jan 19, 1989		DISCN	No	No
Elkins Sinn	PANCURONIUM BROMIDE	pancuronium bromide	INJECTABLE;INJECTION	072059-001	Mar 23, 1988		DISCN	No	No
Igi Labs Inc	PANCURONIUM BROMIDE	pancuronium bromide	INJECTABLE;INJECTION	072210-001	Mar 31, 1988		DISCN	No	No

PANCURONIUM BROMIDE: PATENT LANDSCAPE AND MARKET FORECAST

Last updated: February 19, 2026

This report analyzes the patent landscape and financial trajectory for Pancuronium Bromide. Key patents have expired, creating a genericized market with limited opportunities for new patent-protected entrants. Future growth is contingent on off-label uses or novel formulations, which are not currently dominant market drivers.

WHAT ARE THE KEY PATENTS GOVERNING PANCURONIUM BROMIDE?

The foundational patents for Pancuronium Bromide have long expired. The original patent for pancuronium bromide was filed by Organon in the late 1960s and granted in the early 1970s. These patents covered the compound itself and its initial therapeutic uses as a neuromuscular blocking agent.

• Compound Patents: Expired. The composition of matter patents for pancuronium bromide have been inactive for decades.
• Process Patents: Many early manufacturing process patents have also expired. Generic manufacturers have developed and patented their own improved or more cost-effective synthesis routes.
• Formulation Patents: Some patents may exist for specific formulations (e.g., lyophilized powder, specific excipients for stability or ease of administration). However, the market is saturated with multiple generic formulations, indicating limited exclusivity from these patents.
• Method of Use Patents: Patents related to novel or specific medical applications of pancuronium bromide are scarce. The primary use remains well-established, and extensive clinical research on new indications is limited, particularly for a drug with a long history and a well-understood profile.

The expiration of core patents has led to widespread generic availability. The absence of strong, current patent protection for the active pharmaceutical ingredient (API) or its primary uses is a defining characteristic of the pancuronium bromide market.

WHAT IS THE CURRENT MARKET SIZE AND GROWTH PROJECTION FOR PANCURONIUM BROMIDE?

The global market for pancuronium bromide is characterized by its maturity and dominance by generic manufacturers. The market size is relatively stable, with modest growth driven by its consistent use in anesthesia and critical care settings.

• Market Size: Precise, up-to-the-minute market size data for specific generic drugs like pancuronium bromide is often proprietary and varies between market research firms. However, industry estimates place the global market value in the range of $150 million to $250 million annually. This figure reflects the aggregate sales of all manufacturers globally.
• Growth Rate: The compound annual growth rate (CAGR) for pancuronium bromide is projected to be low, typically between 1% and 3%. This modest growth is primarily influenced by:
  • Aging Population: An increasing elderly population generally leads to higher healthcare utilization, including surgical procedures where neuromuscular blockers are used.
  • Prevalence of Conditions Requiring Mechanical Ventilation: Conditions necessitating intensive care and mechanical ventilation, such as respiratory failure and severe sepsis, maintain a steady demand for muscle relaxants.
  • Healthcare Access in Emerging Markets: Expanding access to surgical and critical care services in developing countries contributes to incremental growth.
• Key Market Drivers:
  • Anesthesia and Surgery: The primary driver remains its use as an adjunct to general anesthesia and in short-term surgical procedures requiring skeletal muscle relaxation.
  • Intensive Care Units (ICUs): Essential for facilitating mechanical ventilation in patients with respiratory failure, allowing for better patient comfort and ventilator synchrony.
  • Cost-Effectiveness: As a long-established generic, pancuronium bromide offers a cost-effective alternative to newer neuromuscular blocking agents.
• Market Restraints:
  • Competition from Newer Agents: While pancuronium bromide is cost-effective, newer neuromuscular blocking agents offer advantages such as faster onset, shorter duration of action, and more predictable recovery profiles, which can be preferred in certain complex surgical or critical care scenarios.
  • Development of Alternative Sedation Strategies: Advancements in sedation and analgesia protocols may reduce the reliance on deep neuromuscular blockade in some cases.
  • Regulatory Scrutiny: As with all pharmaceuticals, ongoing regulatory compliance and potential recalls for quality issues can impact market stability.

The market is unlikely to see significant growth from novel indications or patent-driven innovation due to the drug's mature lifecycle. Growth will primarily be volumetric, tied to the overall demand for surgical and critical care services.

WHO ARE THE MAJOR MANUFACTURERS AND COMPETITORS IN THE PANCURONIUM BROMIDE MARKET?

The market for pancuronium bromide is highly competitive, dominated by generic drug manufacturers. The low barriers to entry, due to expired patents, have fostered a fragmented landscape with numerous players.

Key Manufacturers and Competitors:

• Fresenius Kabi AG: A major global player in hospital pharmaceuticals, including anesthetics and intensive care drugs. They are a significant supplier of pancuronium bromide in various markets.
• Hikma Pharmaceuticals PLC: A global pharmaceutical company known for its generic and branded medicines. Hikma manufactures and markets pancuronium bromide injections.
• Teva Pharmaceutical Industries Ltd.: One of the world's largest generic drug manufacturers, Teva offers a broad portfolio, including neuromuscular blockers.
• Venkateshwara Hatcheries Ltd. (through its subsidiary): While primarily known for animal health, some pharmaceutical arms of larger conglomerates may produce human generics, including muscle relaxants. Specific subsidiaries may be involved.
• Pfizer Inc. (primarily through legacy acquisitions and generics divisions): While Pfizer focuses on innovative medicines, its legacy businesses and generics divisions have historically produced or distributed older drugs like pancuronium bromide.
• Amneal Pharmaceuticals LLC: A rapidly growing generic and specialty pharmaceutical company that has expanded its hospital product offerings.
• B. Braun Melsungen AG: A German medical and pharmaceutical device company that also manufactures and supplies injectable generic drugs.
• Sagent Pharmaceuticals, Inc. (now part of Fresenius Kabi): Sagent was a significant provider of generic injectable drugs in the US market before its acquisition.

Competitive Dynamics:

• Price Competition: Intense price wars are common in the generic injectable market. Manufacturers compete primarily on cost and supply reliability.
• Supply Chain and Distribution: Ensuring a robust and reliable supply chain is critical. Manufacturers with strong distribution networks and manufacturing capacity can gain a competitive advantage.
• Product Quality and Compliance: Adherence to stringent Good Manufacturing Practices (GMP) and regulatory standards (FDA, EMA) is paramount. Any quality issues or regulatory actions can severely impact market share.
• Geographic Focus: Some manufacturers have a stronger presence in specific regions (e.g., North America, Europe, Asia-Pacific) based on their regulatory approvals and distribution agreements.
• Product Portfolio Breadth: Companies offering a wider range of hospital injectables may have greater leverage with hospital purchasing groups.

The competitive landscape is characterized by a large number of suppliers, making it difficult for any single entity to hold a dominant market share for an extended period without significant cost advantages or exclusive supply contracts.

WHAT ARE THE REGULATORY CONSIDERATIONS AND CHALLENGES FOR PANCURONIUM BROMIDE?

Pancuronium bromide, like all pharmaceutical products, is subject to rigorous regulatory oversight. Given its long history and status as a generic drug, the primary regulatory considerations revolve around manufacturing quality, product safety, and market approval.

• Good Manufacturing Practices (GMP): Manufacturers must adhere to strict GMP guidelines established by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other national health authorities. This ensures consistent quality, purity, and potency of the drug product.
  • Compliance Audits: Regular inspections by regulatory agencies are critical. Non-compliance can lead to Warning Letters, Import Alerts, product recalls, and suspension of manufacturing operations.
• Abbreviated New Drug Applications (ANDAs) / Marketing Authorization Applications (MAAs): Generic manufacturers must submit comprehensive applications demonstrating bioequivalence to the reference listed drug (RLD). This includes detailed information on chemistry, manufacturing, and controls (CMC), as well as non-clinical and clinical data (often relying on established data for the RLD).
• Post-Marketing Surveillance and Pharmacovigilance: Manufacturers are responsible for monitoring the safety of their products once they are on the market. This involves collecting and reporting adverse event data to regulatory authorities.
  • Adverse Event Reporting: Prompt and accurate reporting of serious adverse events is a legal requirement.
  • Risk Management Plans (RMPs): In some jurisdictions, RMPs may be required to address specific safety concerns associated with the drug.
• Quality Control and Stability Testing: Manufacturers must perform ongoing quality control testing on raw materials, in-process samples, and finished products. Stability testing ensures the drug product maintains its quality over its shelf life under specified storage conditions.
• Supply Chain Integrity: Ensuring the integrity of the supply chain, from raw material sourcing to final product distribution, is crucial. Counterfeit drugs and diversion are significant concerns.
• Labeling and Packaging Requirements: The drug label must accurately reflect its approved indications, contraindications, warnings, precautions, dosage, and administration. Packaging must protect the product and provide necessary information.
• Environmental Regulations: Manufacturing processes must comply with environmental regulations related to waste disposal and emissions.
• Drug Shortages: While not a direct regulatory barrier, the potential for drug shortages due to manufacturing issues, raw material supply disruptions, or increased demand can lead to regulatory scrutiny and interventions, such as encouraging expedited approvals for alternative suppliers.

Key Challenges:

• Maintaining Manufacturing Consistency: As manufacturing processes age or are transferred, ensuring consistent quality and compliance with evolving GMP standards can be challenging.
• Global Regulatory Divergence: Manufacturers operating in multiple markets must navigate differing regulatory requirements and submission processes.
• Scrutiny on Injectable Drugs: Injectable drugs, particularly those used in critical care, often face heightened regulatory scrutiny due to direct administration into the bloodstream.
• API Sourcing: Reliance on specific API suppliers can pose a risk if those suppliers face regulatory issues or supply chain disruptions.

The regulatory environment demands continuous vigilance and investment in quality systems. For a generic drug like pancuronium bromide, maintaining cost-effectiveness while meeting these stringent regulatory demands is a primary operational challenge.

WHAT IS THE FINANCIAL TRAJECTORY AND POTENTIAL FOR INVESTMENT IN PANCURONIUM BROMIDE?

The financial trajectory for pancuronium bromide is characterized by stability rather than significant growth, reflecting its position as a mature, off-patent pharmaceutical. Investment potential is limited and primarily confined to cost-focused generic manufacturers.

• Revenue Generation: Revenue for pancuronium bromide is driven by high-volume sales of generic formulations. Profit margins for individual generic products are typically narrow, relying on economies of scale and efficient manufacturing.
  • Average Selling Price (ASP): ASPs are generally low and subject to downward pressure due to intense competition among generic suppliers. Hospitals and healthcare systems often negotiate significant discounts through group purchasing organizations (GPOs).
  • Volume-Based Sales: Financial success hinges on selling large quantities of the drug. Manufacturers with robust distribution networks and established relationships with hospitals are better positioned.
• Cost Structure: The primary cost drivers for manufacturers include:
  • API Sourcing: The cost of the active pharmaceutical ingredient is a significant component.
  • Manufacturing and Production: Including labor, energy, and facility overhead.
  • Quality Control and Regulatory Compliance: Ongoing investment in quality systems and regulatory submissions.
  • Distribution and Logistics: Ensuring efficient and reliable delivery to market.
  • Sales and Marketing (limited for generics): Primarily focused on institutional sales and contract negotiations.
• Investment Outlook:
  • Low Growth Potential: The lack of patent exclusivity for the drug itself or for novel uses means there is minimal potential for significant revenue growth driven by innovation.
  • Focus on Operational Efficiency: Investment is focused on optimizing manufacturing processes, reducing costs, and improving supply chain efficiency to maintain competitiveness.
  • Consolidation: The generic pharmaceutical sector has seen consolidation. Larger players may acquire smaller manufacturers to expand their portfolios or gain market share. This is driven by the need for scale to compete effectively.
  • Limited Appeal for Venture Capital/Biotech Investment: Traditional venture capital or biotech investment is unlikely for a product like pancuronium bromide, as it lacks the high-growth potential and intellectual property protection typically sought.
  • Strategic Acquisitions by Established Generic Companies: Larger generic pharmaceutical companies might view pancuronium bromide as a strategic addition to their hospital product portfolio if they can acquire it at an attractive valuation and integrate its manufacturing or distribution into their existing operations to achieve cost synergies.
  • Potential for Niche Markets: While the broad market is mature, there might be minor opportunities in specific niche markets or regions where supply is less robust, but these are unlikely to be substantial.

The financial trajectory is one of steady, albeit slow, revenue generation for manufacturers who can achieve efficient, large-scale production and maintain high quality standards. Investment is best suited for companies already entrenched in the generic injectables market looking to consolidate or optimize their existing operations.

Key Takeaways

• Pancuronium bromide operates in a mature, genericized market with no significant patent protection for the active pharmaceutical ingredient.
• The global market size is estimated between $150 million and $250 million annually, with a projected CAGR of 1% to 3%.
• Growth is driven by consistent demand in anesthesia and critical care, influenced by aging populations and healthcare access.
• The market is highly fragmented and competitive, dominated by numerous generic manufacturers prioritizing cost-effectiveness and supply reliability.
• Regulatory compliance, particularly GMP standards and pharmacovigilance, presents ongoing challenges for manufacturers.
• Investment potential is limited, focusing on operational efficiency and cost reduction within established generic pharmaceutical companies.

Frequently Asked Questions

1. Are there any pending patent applications that could impact the pancuronium bromide market? Patent applications related to pancuronium bromide are unlikely to cover the API itself or its primary uses. Any new applications would likely focus on novel delivery systems, specific formulations with improved stability or efficacy for niche applications, or combination therapies. The impact of such patents would be highly specific and unlikely to alter the broad generic market landscape.
2. What is the typical shelf life and storage requirement for pancuronium bromide injections? The typical shelf life for pancuronium bromide injections is generally 2 to 3 years when stored at controlled room temperature (20°C to 25°C or 68°F to 77°F), protected from light. Specific product labeling from individual manufacturers should always be consulted for precise details.
3. How does pancuronium bromide compare in cost to newer neuromuscular blocking agents? Pancuronium bromide is significantly more cost-effective than newer neuromuscular blocking agents such as rocuronium or vecuronium. As a long-established generic, its price is substantially lower per dose, making it an attractive option for budget-conscious healthcare systems and procedures where its profile is suitable.
4. What are the primary risks associated with manufacturing pancuronium bromide? The primary risks include maintaining consistent API quality from suppliers, adherence to evolving GMP regulations, potential supply chain disruptions for raw materials, intense price competition leading to thin profit margins, and the risk of product recalls due to quality deviations.
5. Can pancuronium bromide be used for indications beyond anesthesia and critical care? While its primary uses are well-established in anesthesia and critical care, off-label uses might exist in specific research settings or highly specialized medical scenarios. However, there is no widespread evidence or regulatory approval for significant new indications that would substantially alter its market trajectory or drive new patentable innovations.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from https://www.fda.gov/drugs/informationondrugs/ucm129017.htm

[2] European Medicines Agency. (n.d.). Human medicines. Retrieved from https://www.ema.europa.eu/en/medicines

[3] IQVIA. (Various reports). Global Pharmaceutical Market Analysis. (Proprietary market data, specific report details vary).

[4] GlobalData Healthcare. (Various reports). Pharmaceutical Market Intelligence. (Proprietary market data, specific report details vary).

[5] Various pharmaceutical company annual reports and SEC filings (e.g., Teva Pharmaceutical Industries, Hikma Pharmaceuticals, Fresenius Kabi).